摘要
预防性人乳头瘤病毒(HPV)疫苗接种覆盖率低严重阻碍了我国和其他资源有限国家实现宫颈癌消除目标,单剂次接种有望缓解HPV疫苗供应短缺的现状。本文对全球单剂次HPV疫苗接种研究进展及应用现状作一综述,结果显示已发表的临床研究和真实世界研究初步证实了单剂次HPV疫苗接种的有效性、免疫原性和安全性;基础研究证实了单剂次诱导的高抗体亲和力及免疫记忆;模型研究提示单剂次策略兼具良好的健康获益和成本效益。基于上述证据,全球26个国家已将单剂次接种程序纳入国家免疫规划。亟需中国人群HPV疫苗单剂次的有效性和安全性的研究证据,以促进单剂次在中国的推广应用。
Low human papillomavirus(HPV)vaccination coverage is a serious impediment to achieving cervical cancer elimination goals in China and other resource-limited countries.Single-dose vaccination is expected to alleviate the shortage of HPV vaccine supply.This paper reviewed the progress of global single-dose HPV vaccination studies and the current implementation status.Several randomized clinical trials and real-world studies have initially shown the protective effect,immunogenicity,and safety of single-dose vaccination;Basic studies have confirmed the high antibody affinity and immune memory induced by single-dose HPV vaccination;Modeling studies have indicated both good health benefits and cost-effectiveness of single-dose vaccination strategies.Until now,26countries have incorporated single-dose vaccination programs into their immunization programs,as recommended by guidelines issued based on the above evidence.There is an urgent need for research evidence on the efficacy and safety of singledose HPV vaccination in Chinese population to promote the implementation of single-dose in China.
作者
文天萌
由婷婷
潘程浩
胡尚英
赵方辉
WEN Tianmeng;YOU Tingting;PAN Chenghao;HU Shangying;ZHAO Fanghui(Department of Epidemiology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing100021,China)
出处
《中华肿瘤防治杂志》
CAS
北大核心
2023年第20期1201-1207,共7页
Chinese Journal of Cancer Prevention and Treatment
基金
国家自然科学基金(82273273)。
关键词
子宫颈癌
人乳头瘤病毒疫苗
单剂次
应用现状
cervical cancer
human papillomavirus vaccines
single-dose
implementation status
